Procyon Advisors, LLC Vertex Pharmaceuticals Inc Transaction History
Procyon Advisors, LLC
- $1.04 Billion
- Q2 2025
A detailed history of Procyon Advisors, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Procyon Advisors, LLC holds 4,428 shares of VRTX stock, worth $2.12 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
4,428
Previous 18,598
76.19%
Holding current value
$2.12 Million
Previous $9.02 Million
78.14%
% of portfolio
0.19%
Previous 0.56%
Shares
16 transactions
Others Institutions Holding VRTX
# of Institutions
1,831Shares Held
233MCall Options Held
1.38MPut Options Held
1.08M-
Capital World Investors Los Angeles, CA28.5MShares$13.7 Billion2.34% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.5MShares$11.3 Billion0.21% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$10.2 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA14.5MShares$6.96 Billion1.6% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.65 Billion0.24% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $123B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...